Microchip Biotechnologies Awarded $6.1M Grant to Build Next-Generation DNA Sequencer
Microchip Biotechnologies Inc. (MBI) has been awarded a $6.1 million grant from the National human genome Research Institute (NHGRI) to develop an innovative nanofluidic technological platform that promises to dramatically reduce the cost of DNA sequencing.
The grant was the largest in a series of eleven awards totaling $38M announced on October 14 by NHGRI (part of the US National Institutes of Health), with the goal of broadening the applications of genomic information in medical research and healthcare. NHGRI's near-term goal is to lower the cost of sequencing a mammalian-sized genome to $100,000 or less, which would enable researchers to sequence the genomes of hundreds or even thousands of people as part of studies to identify genes that contribute to cancer, diabetes and other common diseases.
"We are very pleased to receive this award which recognizes MBI's unique capabilities in developing advanced instrumentation for genomics and DNA sequencing," said Dr. Stevan Jovanovich, the Principal Investigator on the grant and MBI's President and CEO. Dr. Jovanovich was formerly the Vice President for Global Research at Amersham Biosciences. "Our effort will combine the talents of MBI's scientific and engineering staff with some of the leading researchers in the fields of genomics, chemistry, and molecular biology based at U.C. Berkeley, Northwestern University and Columbia University."
MBI plans to build a Microbead INtegrated DNA Sequencer (MINDS) System which will push Sanger-based sequencing toward its ultimate performance limit in a completely automated bench-top system. The MINDS System retains the advantages of current DNA sequencing methods, including well-developed community infrastructure, commercial availability of reagents, and existing base-calling and analysis software, but employs proprietary new technologies that reduce process volumes to the nanoliter scale.
The heart of the MINDS System will be microfabricated glass wafers with on-chip valves, pumps, and routers connecting etched nanofluidic channels that can label, amplify, and purify DNA fragments retained on individual microbeads, followed by ultra-fast separation and analysis of fluorescently-tagged products in etched on-chip electrophoresis channels. The MINDS microchips will replace not only the fused silica capillaries used in current sequencing hardware, but also entire laboratories full of sample preparation equipment. MBI projects that its MINDS System will reduce the cost of current DNA sequencing methodologies by a factor of 100 or more.
Collaborating with MBI to develop important enabling technology related to the amplification and selection of clones and associated nanofluidics will be Professor Richard A. Mathies at U.C. Berkeley, who stated, "MBI is uniquely positioned to exploit the cutting edge technologies developed by our collaborative research. Its team has many years of industrial experience designing and building leading instrumentation platforms used in the life sciences industry."
Also collaborating with MBI will be Professor Annelise Barron at Northwestern University in Illinois, who will develop novel DNA separation matrices for the on-chip etched electrophoresis channels, and Professor Jingyue Ju at the Columbia University Genome Sequencing Center in New York, who will evaluate prototype MINDS Systems as a beta test site.
"Receiving this grant is an important independent validation not only of MBI's technological approach, but also of the scientific and management teams we have assembled to move this important effort forward," said Dr. Robert Stack, MBI's Vice President of Corporate and Business Development. "We believe the MINDS System will provide genome center DNA sequencing capabilities to individual research laboratories at an affordable price. The integration of nanoscale sample preparation and microchip analysis in the MINDS System should help to usher in further advances in biomedical research, health care, and personalized medicine as well as forensics and infectious disease detection."
Other news from the department business & finance
These products might interest you
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
Greener Alternative Products by Merck
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Most read news
More news from our other portals
Last viewed contents
Scientists create first mouse model of typhoid fever - Advance will accelerate testing of new vaccines
Researchers build micro-device to detect bacteria, viruses - New process improves lab-on-chip devices to isolate drug-resistant strains of bacterial infection, viruses
Influenza
Superficial_vein
Bacterial_oxidation
Research on neural dynamics wins 2022 Eppendorf & Science Prize
How to rescue the immune system - Study in Nature Medicine could lead to novel therapy for cancer
